Is CTXR or IMA more profitable?

ImageneBio's return on equity of -38.96% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -61.09% -35.36% ImageneBio N/A -38.96% -34.60%

Which has higher earnings & valuation, IMMP or CTXR?

Citius Pharmaceuticals has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.92 -$39.78M N/A N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is IMMP or CTXR more profitable?

Prima BioMed's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Citius Pharmaceuticals N/A -61.09% -35.36%

Which has higher valuation & earnings, CNTX or CTXR?

Context Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.42 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is CNTX or CTXR more profitable?

Context Therapeutics' return on equity of -59.95% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -59.95% -54.78% Citius Pharmaceuticals N/A -61.09% -35.36%

Does the media prefer CNTX or CTXR?

In the previous week, Context Therapeutics had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 3 mentions for Context Therapeutics and 1 mentions for Citius Pharmaceuticals. Context Therapeutics' average media sentiment score of 1.27 beat Citius Pharmaceuticals' score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BYSI or CTXR?

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 865.25%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is BYSI or CTXR more profitable?

BeyondSpring's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Citius Pharmaceuticals N/A -61.09% -35.36%

Citius Pharmaceuticals (CTXR) Competitors

$0.52 +0.04 (+7.78%)

As of 10:37 AM Eastern

Compare

CTXR vs. IMA, IMMP, CNTX, XLO, and BYSI

Should you buy Citius Pharmaceuticals stock or one of its competitors? MarketBeat compares Citius Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Citius Pharmaceuticals include ImageneBio (IMA), Prima BioMed (IMMP), Context Therapeutics (CNTX), Xilio Therapeutics (XLO), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does Citius Pharmaceuticals compare to ImageneBio?

Citius Pharmaceuticals (NASDAQ:CTXR) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Citius Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ImageneBio's return on equity of -38.96% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
ImageneBio	N/A	-38.96%	-34.60%

Citius Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 865.25%. ImageneBio has a consensus target price of $26.50, indicating a potential upside of 367.78%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Citius Pharmaceuticals is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than ImageneBio. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for ImageneBio. Citius Pharmaceuticals' average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company	Overall Sentiment
Citius Pharmaceuticals	Neutral
ImageneBio	Neutral

Citius Pharmaceuticals has higher earnings, but lower revenue than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
ImageneBio	$800K	75.42	-$45.35M	-$5.79	N/A

Summary

Citius Pharmaceuticals beats ImageneBio on 9 of the 14 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Prima BioMed's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

Prima BioMed has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Prima BioMed. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Prima BioMed	Neutral
Citius Pharmaceuticals	Neutral

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Citius Pharmaceuticals has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.92	-$39.78M	N/A	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

Prima BioMed currently has a consensus target price of $5.50, suggesting a potential upside of 1,258.02%. Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 865.25%. Given Prima BioMed's higher possible upside, equities research analysts clearly believe Prima BioMed is more favorable than Citius Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Citius Pharmaceuticals beats Prima BioMed on 6 of the 11 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Context Therapeutics currently has a consensus price target of $6.17, indicating a potential upside of 899.46%. Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 865.25%. Given Context Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Context Therapeutics is more favorable than Citius Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Context Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Context Therapeutics' return on equity of -59.95% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

In the previous week, Context Therapeutics had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 3 mentions for Context Therapeutics and 1 mentions for Citius Pharmaceuticals. Context Therapeutics' average media sentiment score of 1.27 beat Citius Pharmaceuticals' score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Summary

Context Therapeutics beats Citius Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Xilio Therapeutics?

Citius Pharmaceuticals (NASDAQ:CTXR) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Citius Pharmaceuticals has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Citius Pharmaceuticals' return on equity of -61.09% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for Xilio Therapeutics. Citius Pharmaceuticals' average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score.

Company	Overall Sentiment
Citius Pharmaceuticals	Neutral
Xilio Therapeutics	Neutral

Xilio Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
Xilio Therapeutics	$43.77M	1.31	-$35.04M	-$3.55	N/A

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Citius Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 865.25%. Xilio Therapeutics has a consensus target price of $28.00, indicating a potential upside of 220.11%. Given Citius Pharmaceuticals' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Citius Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market.

Summary

Citius Pharmaceuticals beats Xilio Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BeyondSpring has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 865.25%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than BeyondSpring. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
Citius Pharmaceuticals	Neutral

BeyondSpring's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

BeyondSpring has higher revenue and earnings than Citius Pharmaceuticals. BeyondSpring is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	30.10	-$1.01M	-$0.14	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

Summary

BeyondSpring beats Citius Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Citius Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTXR vs. The Competition

Export

Metric	Citius Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.22M	$3.06B	$6.80B	$12.37B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.24	20.36	27.09	24.07
Price / Sales	N/A	346.34	520.26	91.86
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.12	4.23	10.64	6.20
Net Income	-$37.43M	$65.94M	$3.60B	$331.63M
7 Day Performance	-2.63%	-2.16%	-1.41%	-1.54%
1 Month Performance	-5.20%	-0.50%	0.97%	-1.17%
1 Year Performance	-64.03%	16.28%	24.23%	17.81%

Citius Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTXR Citius Pharmaceuticals	1.9058 of 5 stars	$0.52 +7.8%	$5.00 +865.3%	-68.6%	$14.22M	N/A	N/A	20	News Coverage Gap Up
IMA ImageneBio	2.0295 of 5 stars	$6.11 +3.4%	$26.50 +333.7%	-62.4%	$62.97M	$800K	N/A	70
IMMP Prima BioMed	2.0576 of 5 stars	$0.45 +7.5%	$5.50 +1,120.9%	-76.0%	$61.75M	$6.69M	N/A	2,021	Gap Down
CNTX Context Therapeutics	3.2198 of 5 stars	$0.62 -4.5%	$6.17 +888.6%	-30.8%	$59.99M	N/A	N/A	7	News Coverage Positive News Analyst Downgrade
XLO Xilio Therapeutics	1.9542 of 5 stars	$9.24 +1.5%	$28.00 +203.0%	-15.2%	$59.83M	$43.77M	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTXR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. IMA, IMMP, CNTX, XLO, and BYSI

How does Citius Pharmaceuticals compare to ImageneBio?

Summary

How does Citius Pharmaceuticals compare to Prima BioMed?

Summary

How does Citius Pharmaceuticals compare to Context Therapeutics?

Summary

How does Citius Pharmaceuticals compare to Xilio Therapeutics?

Summary

How does Citius Pharmaceuticals compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. IMA, IMMP, CNTX, XLO, and BYSI

How does Citius Pharmaceuticals compare to ImageneBio?

Which has more risk & volatility, CTXR or IMA?

Do institutionals and insiders believe in CTXR or IMA?

Is CTXR or IMA more profitable?

Do analysts prefer CTXR or IMA?

Does the media favor CTXR or IMA?

Which has higher valuation and earnings, CTXR or IMA?

Summary

How does Citius Pharmaceuticals compare to Prima BioMed?

Is IMMP or CTXR more profitable?

Which has more risk & volatility, IMMP or CTXR?

Does the media favor IMMP or CTXR?

Do insiders & institutionals have more ownership in IMMP or CTXR?

Which has higher earnings & valuation, IMMP or CTXR?

Do analysts rate IMMP or CTXR?

Summary

How does Citius Pharmaceuticals compare to Context Therapeutics?

Do analysts recommend CNTX or CTXR?

Which has higher valuation & earnings, CNTX or CTXR?

Do insiders and institutionals believe in CNTX or CTXR?

Is CNTX or CTXR more profitable?

Does the media prefer CNTX or CTXR?

Which has more risk and volatility, CNTX or CTXR?

Summary

How does Citius Pharmaceuticals compare to Xilio Therapeutics?

Is CTXR or XLO more profitable?

Does the media favor CTXR or XLO?

Which has better valuation & earnings, CTXR or XLO?

Do insiders & institutionals believe in CTXR or XLO?

Do analysts recommend CTXR or XLO?

Which has more risk & volatility, CTXR or XLO?

Summary

How does Citius Pharmaceuticals compare to BeyondSpring?

Do insiders and institutionals hold more shares of BYSI or CTXR?

Which has more volatility & risk, BYSI or CTXR?

Do analysts recommend BYSI or CTXR?

Does the media prefer BYSI or CTXR?

Is BYSI or CTXR more profitable?

Which has better valuation & earnings, BYSI or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools